Literature DB >> 29428281

Cell-Free DNA Screening for Aneuploidy and Microdeletion Syndromes.

Brian L Shaffer1, Mary E Norton2.   

Abstract

Cell-free DNA (cfDNA) screening for the common aneuploidies is an accurate noninvasive screen for the common autosomal and sex chromosome aneuploidies. However, cfDNA screening should not be considered a diagnostic test, and the positive predictive value should be used in counseling women with a positive test regarding the option for diagnostic testing. Compared with traditional screening, cfDNA may not detect as many chromosomal abnormalities of importance. Furthermore, due to the low prevalence of recurrent copy number variants, the clinical utility in screening for microdeletions and duplications is uncertain and is not recommended for the general obstetric population.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aneuploidy screening; Cell-free DNA screening; Noninvasive prenatal testing; Prenatal diagnosis; Prenatal screening

Mesh:

Substances:

Year:  2018        PMID: 29428281     DOI: 10.1016/j.ogc.2017.10.001

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  4 in total

Review 1.  Recent trends in prenatal genetic screening and testing.

Authors:  Ondrej Pös; Jaroslav Budiš; Tomáš Szemes
Journal:  F1000Res       Date:  2019-05-31

2.  Factors affecting cell-free DNA fetal fraction: statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening.

Authors:  Yaping Hou; Jiexia Yang; Yiming Qi; Fangfang Guo; Haishan Peng; Dongmei Wang; Yixia Wang; Xiaohui Luo; Yi Li; Aihua Yin
Journal:  Hum Genomics       Date:  2019-12-04       Impact factor: 4.639

Review 3.  Validity and Utility of Non-Invasive Prenatal Testing for Copy Number Variations and Microdeletions: A Systematic Review.

Authors:  Luca Zaninović; Marko Bašković; Davor Ježek; Ana Katušić Bojanac
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

4.  Enrichment of circulating trophoblasts from maternal blood using filtration-based Metacell® technology.

Authors:  Jana Weymaere; Ann-Sophie Vander Plaetsen; Yasmine Van Den Branden; Eliska Pospisilova; Olivier Tytgat; Dieter Deforce; Filip Van Nieuwerburgh
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.